InterMune
Boehringer gains EU approval for Ofev
January 19, 2015Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev
The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …
Roche buys Ariosa Diagnostics
December 2, 2014Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon
Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …
Boehringer and Roche IPF drugs win FDA approval
October 16, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev
The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …
InterMune’s IPF drug shines at ERS Congress
September 10, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone
InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …
Roche pays $8.3bn for InterMune
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Genentech, IPF, Illumina, InterMune, Roche
Roche has stumped up $8.3 billion in cash to pay for US biotech firm InterMune and will gain access to …
InterMune stock jumps on suitor claims
August 14, 2014Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune
Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …
Shortlist announced for best new pharma product
June 24, 2014Research and Development, Sales and Marketing Esbriet, InterMune, Lemtrada, Orphan, dificlir, innovative, pif, prix galion, selincro
Treatments for idiopathic pulmonary fibrosis, hepatic encephalopathy and meningococcal infection are among 14 new medicines shortlisted for the UK Prix …
InterMune drops EMA lawsuit over data release
June 10, 2014Research and Development, Sales and Marketing EMA, EU, Esbriet, Goldacre, InterMune, alltrials, lung
InterMune has ended a year-long legal spat with the European Medicines Agency over the potential release of data for its …
Boehringer and InterMune data on IPF drugs impress
May 19, 2014Research and Development, Sales and Marketing Boehringer Ingelheim, InterMune, idiopathic pulmonary fibrosis
Two new medicines for a generally fatal lung disease, known as idiopathic pulmonary fibrosis and made by Boehringer and InterMune, …
EMA transparency agenda sees more delay
April 9, 2014Medical Communications, Sales and Marketing AbbVie, EFPIA, EMA, Europe, InterMune, alltrials, parliament, transparency
The European Medicines Agency is to further delay its policy over clinical trial transparency, saying it needs more time to …
InterMune scores in lung trial
February 26, 2014Research and Development, Sales and Marketing Esbriet, FDA, IPF, InterMune, fvc, lung
InterMune has taken another step on its lengthy road to get the US regulator to approve its drug Esbriet for …
Court annuls EMA data decision
December 5, 2013Medical Communications, Sales and Marketing AbbVie, EMA, Goldacre, InterMune, alltrials, transparency
The European Court of Justice has annulled interim injunctions against the European Medicines Agency issued earlier this year after AbbVie …
First idiopathic pulmonary fibrosis drug approved
March 4, 2011Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug
The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
